Our Mission

As Emmert Wolf said, “A man is only as good as his tools”. Something about him, and his gender normativity, is a bit old-fashioned. But the guy had a point. And when it comes to synthetic biology, we’re building the biodesign and bioanalysis tools that the industry has been waiting for.

We’re convinced that humanity’s future on Earth and beyond isn’t just concerned with biodesign. It’s dependent on it. That’s why our sights are set on making biodesign more intuitive, collaborative and essential. With every decision we make and each piece of software we develop, we’re catalyzing some of the most ambitious projects ever undertaken.

Abundant, nutritious, cruelty-free foods. Drugs to overcome even the most persistent diseases. Organisms that will terraform distant planets. The potential applications truly are as limitless as the human imagination – there’s no telling where the future could take us. By providing smarter tools, we’re freeing up minds, amplifying creativity, and empowering synthetic biologists to decide precisely how the future will look.

OUR HISTORY

What's in a name?

Eli, our CEO, started 2015 with a tough departure from his previous company. His values and those of his cofounders had drifted apart to the point that the best way to make a positive impact was simply to leave and start from scratch.

For most of the year, his days started the same way. He’d put on a Tupac album, get to work and think about his next steps. When the stressful protracted process of divesting himself from his former business finally ended favorably, Eli was free to pursue a goal he was committed to – revolutionizing the biodesign landscape. The very same day, he incorporated Tupac.Bio.

Tupac Shakur wasn’t the first to take up the name, and he isn’t the last. It bears a long-standing association with revolution - with rising above adversity and standing up for a cause. Our backgrounds, worldviews and goals may be a million miles apart from our predecessors, but it’s the same revolutionary spirit that inspires us do what we do every day.

New beginnings

One person alone would make for a poor revolution. Paul Sheridan, our Chief Science Officer brought additional extensive experience in bioinformatics and statistics. Add to that the full-stack software engineering chops of our CTO, Justin Kovalchuk, and you’ve got a well-rounded core leadership team that’s ready for anything. With this experienced team of cofounders and some of the industry’s most knowledgeable advisors, Tupac was built from the ground up with biodesign in mind.

Based in the US and Japan, we’re now supporting some of the most innovative companies in synthetic biology. That started with Yamagata-based Spiber, with whom we’ve been working to consistently improve and diversify our tools. Our recent relationship with California-based client, Finless Foods, has only served to bolster our rapidly expanding toolset.

We’re not just ready for adversity. We’re born from it. And we’re here to solve challenging problems in biodesign and bioanalysis.

Get in touch today and let us know how we can help.

OUR TEAM

Eli Lyons
CEO

Eli is a PhD candidate in the Department of Computational Biology and Medical Science at the University of Tokyo. He has an MSc in computer engineering. Troublesome.

Learn more
Eli Lyons

Paul Sheridan
PHD, CSO

Paul has made various contributions to the theory and application of statistics in biology, including integrative multi-omics analysis. He's our stats superman.

Learn more
Paul Sheridan

Justin Kovalchuk
CTO

Justin has expertise in software development processes, full-stack design, and deployment. Coding since Run and them was singin' "Here We Go".

Justin Kovalchuk
Charlane Cardos, M.S.
Research Associate
NICK MULIADI, M.B.A.
Finance Associate
JUSTIN MAK
Front End Developer
DAYNE BARTON
Media Design
KHALID ALAM, PHD
Research Consultant

ADVISORS

HIROKI SUGA, PHD
Dr. Suga is the co-founder of Peptidream (2013 IPO) and professor at University of Tokyo. He is a voluntary advisor.

ROBERT KNELLER, JD, MD, MPH
Dr. Kneller has advanced degrees in multiple areas. He is a professor at University of Tokyo and is involved in vaccine development as well as analysis of the Japanese startup landscape.

YUKI SHIRATO, ESQ
Yuki is an angel investor and corporate lawyer working in mergers and acquisitions.